Cargando…
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
Sodium glucose co-transporter (SGLT-2) inhibitor is a relatively new medication used to treat diabetes. At present, the Food and Drug Administration (FDA) has only approved three medications (canagliflozin, dapagliflozin and empagliflozin) in this drug class for the management of Type 2 diabetes. In...
Autores principales: | Candelario, Nellowe, Wykretowicz, Jedrzej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962888/ https://www.ncbi.nlm.nih.gov/pubmed/27471597 http://dx.doi.org/10.1093/omcr/omw061 |
Ejemplares similares
-
The Case of the Infection that Wasn't !
por: Eatrides, Jennifer, et al.
Publicado: (2009) -
Empagliflozin: Euglycemic and hyperglycaemic diabetic ketoacidosis: case report
Publicado: (2021) -
The Klatskin Tumor That Wasn’t: An Unusual Presentation of Sarcoidosis
por: Farooq, Priya D., et al.
Publicado: (2016) -
Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports
por: Altowayan, Waleed M.
Publicado: (2022) -
What if funding wasn't an issue?
por: Marshall, Laura
Publicado: (2021)